TScan Therapeutics, Inc.
TCRX· Nasdaq
TCRXTScan Therapeutics, Inc.
Filed Aug 19, 2021 · 10-Q · 50 days after period end · 0001564590-21-045079
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Revenue | $2.85M | — |
| Net Income | -$10.67M | -$5.61M |
| EPS Diluted | -$7.69 | -$6.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 19, 2021 · 50 d after period end
